Luis Gutiérrez and John K. Hsu join the growing collaboration being BHI and NIH in 2023
ROCKVILLE, MARYLAND, January 23, 2021 – BioHealth Innovation Inc. (BHI) announces the addition of Luis Gutiérrez and John K. Hsu, Ph.D., J.D., to the growing Entrepreneurs-in-Residence (EIR) team. Luis will work with the NIH Office of Extramural Research (OER), while John will work with The National Heart, Lung, and Blood Institute (NHLBI).
The OER manages the NIH’s extramural research program, providing guidance and support to staff, grantees, and the public on funding opportunities, policies, and regulations. It also oversees the review, award, and administration of grants and contracts for biomedical and behavioral research conducted outside of the NIH. In addition, the NHLBI conducts and supports research on the causes, prevention, diagnosis, and treatment of heart, blood vessel, lung, and blood diseases. It also works to improve the health of individuals and populations through education and public health initiatives.
“We’re proud to add John to our team and bring Luis back to an EIR role with BHI,” said Richard Bendis, BHI President, and CEO. “Our partnership with The NIH in the BioHealth Capital Region, fosters collaboration to accelerate the development and commercialization of cutting-edge technologies and treatments for some of our time’s most pressing health challenges.”
Bethesda-based Gutiérrez is an expert in helping novel technologies transition to commercial success. He currently serves as an independent consultant to medical product companies and investors active in the biopharmaceutical, medical product, and life sciences markets.
Luis Gutiérrez served as Chief Commercial Officer of Veranex, Inc., and as President, CEO, and Board Member of Theranostics Health (now TheraLink Technologies), a start-up molecular diagnostics company that provides proteomic testing services to oncologists, academic institutions, and the biopharmaceutical industry. Between his tenures at Theranostics Health and Veranex, Gutiérrez served five years as an Entrepreneur-In-Residence with BioHealth Innovation and the National Institutes of Health and is currently a part-time “Executive in Residence” with BHI, a position dedicated to providing 1:1 technical assistance to Montgomery County-based biotech and medtech startups.
John K. Hsu has over twenty years of experience evaluating intellectual property matters, including litigating more than sixty patent, trademark, and trade secret cases involving varying technologies such as pharmaceutical drugs, medical devices, computer software, and food processing technology.
Since 2006, Dr. Hsu has focused on pharmaceutical litigation representing drug manufacturers in high-stakes patent litigation brought under the Hatch-Waxman Act. He has utilized his strong chemistry background and depth of scientific knowledge, and trial experience to develop discovery and trial strategies for effective court and trial presentations and favorable settlements. Dr. Hsu has been a member of trial teams throughout all litigation phases, including jury and bench trials before the federal district courts, the Court of Appeals for the Federal Circuit, the Supreme Court of the United States, and the United States International Trade Commission. He also managed patent portfolios and prosecuted patents before the United States Patent and Trademark Office.
Dr. Hsu earned his bachelor’s in biology from The Johns Hopkins University, his Ph.D. in chemistry from the University of Maryland, College Park, and his J.D. from the University of Maryland Francis King Carey School of Law.
About BioHealth Innovation, Inc.
BioHealth Innovation, Inc. (BHI) is a public-private nonprofit organization focused on accelerating biohealth (therapeutic, diagnostic, medtech, and health IT) commercialization in the BioHealth Capital Region (Maryland, DC, and Virginia). BHI’s team of expert Entrepreneurs-in-Residence, in-house venture analysts, and other professional staff work in the region to:
- Facilitate technology commercialization,
- Raise the profile of the industry cluster and individual organizations,
- Increase access to capital for early-stage and growing companies, and
- Expand the pool of talent with commercially relevant experience.
BHI’s early-stage company support includes market research and commercialization plan development, non-dilutive funding application assistance; a jobs board; event calendar; and introductions to investors, strategic partners, business advisors, and potential clients. BHI also manages wet lab space and provides referrals to other spaces for early-stage companies, offers soft-landing support for international companies, and works with partners to co-host the annual BioHealth Capital Region Forum and an annual BioHealth Capital Region investor partnering conference. For more information: www.BioHealthInnovation.org
# # #
Media contacts:
Rich Bendis
Phone: 301-637-6439, email: rbendis@biohealthinnovation.org